ACP-105 is a selective androgen receptor modulator (SARM) primarily investigated for its potential in treating neuromuscular and cognitive disorders. It shows promise in preclinical studies for improving muscle strength and cognitive function without the side effects typically associated with traditional androgen therapies. Research suggests ACP-105 may be beneficial in conditions such as spinal cord injury, muscular dystrophy, and neurodegenerative diseases like Alzheimer's due to its ability to cross the blood-brain barrier and exert tissue-selective anabolic effects. It is also being explored for use in age-related muscle loss and osteoporosis, where maintaining lean mass and bone density is critical. Due to its neuroprotective properties, ACP-105 has gained interest in developing treatments that support both physical and cognitive health in aging populations.